logo

Royality Med Pharmaceuticals Group

Royality Med's mission is to fast-track the early stage of drug discovery using our predictive models of the human brain for therapeutic success. Many neurodevelopmental diseases do not have treatments due to a lack of a-priori knowledge of the underlying biology. Royality Med's technology is able to model these diseases to help enable the discovery of new targets and drugs, de-risking the current failure-prone cumbersome approach.
For inquiries, please contact us at
E-mail: info@royalitymedgrp.com
mobile-logo

Looking ahead with the leading minds in transforming the pharmaceutical cold chain

At Royality Med Pharmaceuticals Group (RMP), we are dedicated to developing a new class of drugs with targeted mechanisms of action, striving to deliver innovative therapies that address diseases with substantial unmet medical needs.

Clinical Pipeline

At RMPG, we boast one of the industry’s most competitive pipelines, featuring over 150 projects currently in clinical development.

In Medicine

Our unique molecules are rationally designed to precisely target key pathways across a broad spectrum of diseases.

Collaborations

Royality Med Pharmaceuticals Group (RMPG) continually forges partnerships with industry leaders to accelerate research and product development.

25+
Years Industry Experience
8 Billion
Dose Manufacturing Capacity
60 Million
Unit Packaging Capacity
200+
OTC and Nutritional Supplement Products

A transformative therapy centered around patient outcomes

Millions worldwide suffer from life-threatening conditions that have significant unmet medical needs and no available cures. Since 2017, a dedicated team of experienced physicians, award-winning scientists, and biotech innovators at Royality Med Pharmaceuticals Group (RMPG) has united to respond to the urgent demand for new treatments.

 

We are all impacted by these diseases directly or indirectly as patients, loved ones, caregivers and healthcare professionals.

qodef-fullwidth-slider

Our Technology: A Novel Approach to Discovering Cures for Neuro-Diseases

Royality Med Pharmaceuticals Group’s (RMPG) technology is a powerful, high-throughput organoid-like platform that rapidly mimics human brain development. We possess an unprecedented ability to identify and quantify differences between diseased and healthy cells—what we term “neuroloids.” Leveraging our advanced machine-learning algorithms, we can detect which compounds effectively reverse diseased cells back to a healthy state, thereby predicting a drug’s potential therapeutic impact on human brain tissue.


I would like to learn about Royality Med’s Pharmaceuticals Group discoveries to treat genetic diseases.


YES, TELL ME MORE